Pyxis Oncology, Inc.·4

Mar 25, 5:10 PM ET

FLAVIN JOHN L 4

4 · Pyxis Oncology, Inc. · Filed Mar 25, 2026

Research Summary

AI-generated summary of this filing

Updated

Pyxis Oncology (PYXS) Director John L. Flavin Receives 45,867‑Share Option

What Happened

  • Director John L. Flavin received a grant (derivative award) on 2026-03-24 for 45,867 shares. The Form 4 reports the acquisition price as $0.00 (award/option), indicating this is a compensation grant rather than an open‑market purchase or sale.

Key Details

  • Transaction date: 2026-03-24; filing date: 2026-03-25 (timely).
  • Transaction type/code: A = Award/Grant of a derivative security (option).
  • Shares subject: 45,867 option shares; reported price: $0.00.
  • Vesting: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to continued service (per footnote F1).
  • Shares owned after transaction: Not disclosed in this filing.
  • No indication of a 10b5‑1 plan, cashless exercise, sale, or tax‑withholding reported here.

Context

  • This was an option award (derivative grant), not an exercise or sale—no immediate proceeds or share sales occurred. Such grants are commonly part of executive/director compensation and reflect long‑term incentive alignment, but do not by themselves indicate buying or selling sentiment. The award vests in one year if the director remains in service.

Insider Transaction Report

Form 4
Period: 2026-03-24
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1]
    2026-03-24+45,86745,867 total
    Exercise: $1.36Exp: 2036-03-24Common Stock (45,867 underlying)
Footnotes (1)
  • [F1]The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Signature
/s/ Jitendra Wadhane, Attorney-in-Fact for John Flavin|2026-03-25

Documents

1 file
  • 4
    ownership.xmlPrimary

    4